Biotechnology and Pharmaceuticals · global
Harnessing Cells to Clear Disease-Causing Proteins: Protein Degrader Drugs Move Toward Clinical Validation
Protein degradation technology, drawing heavy investment from drugmakers, is building treatment evidence in multiple myeloma. One combination therapy has received U.S. accelerated approval, while another has entered regulatory review; how far this new approach can go still depends on whether efficacy is sustained and the safety costs of clearing proteins.
Some disease-causing proteins are central to disease but lack sites where drugs can readily bind and block their function. Protein degrader drugs attempt a different approach: mobilizing the cell’s existing disposal system to send target proteins for breakdown. The Wall Street Journal reported in October that major drugmakers are investing billions of dollars in this field, while clinical and regulatory progress in multiple myeloma is beginning to provide concrete support for this investment boom.
At the heart of these technologies is bringing a target protein close to an E3 ubiquitin ligase, which recognizes and tags proteins, so that the target can be tagged and then broken down by the proteasome. PROTACs bind the target and the E3 ligase at their respective ends, while “molecular glues” promote or stabilize contact between the two. This gives researchers an opportunity to address some proteins that are difficult to tackle with conventional inhibitors, but success still depends on whether each protein interaction is amenable to manipulation by a drug.
On August 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to iberdomide (brand name Zenbexus), in combination with daratumumab and hyaluronidase-fihj and dexamethasone, to treat adults with multiple myeloma who had received at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory drug. In the EXCALIBER-RRMM trial supporting the approval, 41% of patients in the treatment group achieved a “minimal residual disease-negative complete response,” compared with 21% in the control group, in the primary efficacy analysis population. This means that more patients achieved a deep response under the specified testing conditions; it cannot be directly interpreted as a cure or longer survival.
Another development comes from Bristol Myers Squibb’s mezigdomide. The company announced in July that the FDA had accepted its application for approval in combination with carfilzomib and dexamethasone, with a target review date of May 13, 2027. According to the company’s reported Phase 3 SUCCESSOR-2 results, among the 479 patients included in the analysis, progression-free survival was 18.0 months with the combination therapy, compared with 8.3 months in the control group; the hazard ratio for disease progression or death was 0.48. This measure reflects the duration of disease control and does not yet establish an overall survival benefit.
Mezigdomide promotes the degradation of Ikaros and Aiolos proteins by modulating cereblon, a component of an E3 ligase complex. It also serves as a reminder that protein degradation is not an entirely new concept that has suddenly emerged: some existing immunomodulatory drugs for multiple myeloma have long used related biological mechanisms. Today’s research and development race aims to design this activity more precisely and extend the range of targets that can be addressed to more diseases.
Clearing proteins creates treatment opportunities but also requires strict definition of safety limits. The FDA states that iberdomide’s prescribing information carries a boxed warning for embryo-fetal toxicity and serious venous and arterial thrombosis, and that the drug must be provided through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. These risks are specific regulatory requirements for this drug and cannot be directly applied to all protein degrader drugs, but they demonstrate that new mechanisms of action still require individual safety evaluation.
The strongest evidence so far is concentrated in specific combination therapies for myeloma and cannot be extrapolated to all proteins that are difficult to target with drugs or to other cancers. Iberdomide received accelerated approval, and acceptance of mezigdomide’s application does not amount to marketing authorization. For this field, the weight of the next step will come from longer-term data on disease control, survival and safety, and from whether new targets can deliver the same therapeutic value in humans.